Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Kala Pharmaceuticals announced that it will present data from a previously completed phase 1b clinical trial of KPI-012 in a poster session at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, Colorado, May 1-4, 2022 and virtually, May 11-12, 2022. The data support the ongoing development of KPI-012, a novel investigational secretome therapy, to address the complex wound healing process in persistent corneal epithelial defect (PCED).

The accepted abstract is listed below and is now available on the ARVO conference website: https://www.arvo.org/annual-meeting/.

Title: Results of a Phase 1b clinical trial of KPI-012, a novel secretome therapy, in patients with Persistent Corneal Epithelial Defect (PCED)
Session Title: Corneal epithelial biology and repair mechanisms
Presentation Number - Posterboard Number: 3232 - A0267
Date: Tuesday, May 3, 2022
Time: 3:30 – 5:30 p.m. MDT (5:30 – 7:30 p.m. EDT)
Presenter: Valeria Sáanchez-Huerta, M.D., Director General, Asociación para Evitar la Ceguera en México